Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
QuintilesIMS
Boehringer Ingelheim
Queensland Health
Fish and Richardson
Johnson and Johnson
Teva
Fuji
Mallinckrodt
US Army

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,246,979

« Back to Dashboard

Which drugs does patent 8,246,979 protect, and when does it expire?


Patent 8,246,979 protects NEUPRO and is included in one NDA. There has been one Paragraph IV challenge on Neupro.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 8,246,979

Title:Transdermal delivery system for the administration of rotigotine
Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
Inventor(s): Schacht; Dietrich Wilhelm (Koln, DE), Hannay; Mike (Wachtberg-Villiprott, DE), Wolff; Hans-Michael (Monheim, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:10/623,864
Patent Claim Types:
see list of patent claims
Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-004Apr 2, 2012RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-004Apr 2, 2012RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-001May 9, 2007RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-001May 9, 2007RXYesYes► Subscribe► Subscribe► SubscribeYTREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-005Apr 2, 2012RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-005Apr 2, 2012RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-002May 9, 2007RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-002May 9, 2007RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-003May 9, 2007RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
Ucb IncNEUPROrotigotineFILM, EXTENDED RELEASE;TRANSDERMAL021829-003May 9, 2007RXYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,246,979

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02016860Jul 30, 2002

Non-Orange Book Patents for Patent: 8,246,979

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,617,591Transdermal delivery system for the administration of rotigotine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,246,979

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland217079► Subscribe
Poland374814► Subscribe
Norway333297► Subscribe
Norway20050472► Subscribe
MexicoPA05000350► Subscribe
South Korea101016838► Subscribe
South Korea20050056942► Subscribe
Japan5564469► Subscribe
Japan2011219485► Subscribe
Japan4837916► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
Fuji
Argus Health
Deloitte
Chubb
AstraZeneca
Healthtrust
Farmers Insurance
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot